(2021) showed that PSMD4 is a potential target in mouse colorectal cancer, mediating the enhancement of immunoproteasome activity by atractylenolide I (ATT-I), making the body more responsive to immune checkpoint blocking therapy. This evidence concerns the gene PSMD4 and colorectal cancer.